Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secure full stability against metabolic degradation. The fatty acid moiety and the linking chemistry to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analogue. Semaglutide was selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased. The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs. Semaglutide is currently in phase 3 clinical testing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The elimination half-life of 7 (Table 2), as measured after i.v. dose in minipigs, could be increased by nearly 40% through the replacement of the C18 diacid protractor with a C20 diacid (8), providing an even more attractive PK profile for potential once-weekly clinical administration when compared to the once-weekly GLP-1R agonist semaglutide [47].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [47]
In the citing paper
“We estimated the required sample size to be 60 participants (30 for oral and 30 for subcutaneous semaglutide), assuming a two-sided hypothesis test with a 95% confidence level and accounting for a potential 10% loss. This estimation was based on a minimum clinically relevant difference of -10% in fat body mass at the conclusion of the follow-up (22, 23).”
From Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus (2024) · cites this paper as [22]
In the citing paper
“Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week (which permits once-weekly subcutaneous administration), 4”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [4]
In the citing paper
“The long half-life of semaglutide (approximately 7.5 hours in mice, 12 hours in rats, and 183 hours in humans) makes it suitable for once-weekly administration in humans (43, 48–50).”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [48]
In the citing paper
“This formulation results in slower degradation and a half-life 155 to 184 hours, allowing for once-weekly subcutaneous dosing without compromising weight loss efficacy.(11, 26)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [26]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Schuck, P. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76713-0 · Cited by 3,868
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Fatty acid binding to plasma albumin
Spector, A. A. (1975) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)36723-7 · Cited by 966
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Fatty acid binding to human serum albumin: new insights from crystallographic studies
Curry, S., Brick, P., & Franks, N. P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(99)00148-1 · Cited by 495
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Research works printed but not linked: 1
- 10.1016/s0140-6736(09)60659-0 · DOI · Paper page
Cited by
Items 101–200 of 1,000
Tran, K., Park, Y. I., Pandya, S., Muliyil, N. J., Jensen, B. D., Huynh, K., & Nguyen, Q. P. H. (2017) · PubMed Central · Cited by 127
Clinical Pharmacokinetics of Semaglutide: A Systematic Review
Yang, X., & Yang, X. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s470826 · Cited by 120
“20 21–26 In addition, semaglutide significantly improved cardiovascular outcomes.”
BackgroundResultPharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
Bækdal, T. A., Thomsen, M., Kupčová, V., Hansen, C. W., & Anderson, T. W. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1131 · Cited by 95
“Mean (SD) age, years 49 (11) 52 (10) 54 (10) 52 (8)”
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Johannsson, G., Gordon, M. B., Højby Rasmussen, M., Håkonsson, I. H., Karges, W., Sværke, C., Tahara, S., Takano, K., & Biller, B. M. K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa049 · Cited by 83
“This is a well-established technique that has been used successfully to extend the half-lives of insulin detemir (11) and the glucagon-like peptide-1 (GLP-1) agonists liraglutide (12) and once-weekly semaglutide (13).”
MethodMultifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
Guerra, J. V. D. S., Dias, M. M. G., Brilhante, A. J. V. C., Terra, M. F., García‐Arévalo, M., & Figueira, A. C. M. (2021) · Nutrients · doi:10.3390/nu13082830 · Cited by 113
Semaglutide: review and place in therapy for adults with type 2 diabetes
Goldenberg, R. M., & Steen, O. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.05.008 · Cited by 91
Advances in oral peptide drug nanoparticles for diabetes mellitus treatment
Li, Y., Zhang, W., Zhao, R., & Zhang, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.02.025 · Cited by 117
New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling
Tomas, A., Jones, B., & Leech, C. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.08.009 · Cited by 86
Hampton, J. T., & Liu, W. R. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00004 · Cited by 97
Photo-induced radical thiol–ene chemistry: a versatile toolbox for peptide-based drug design
Ahangarpour, M., Kavianinia, I., Harris, P. W. R., & Brimble, M. A. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00354a · Cited by 93
Lac-Phe mediates the effects of metformin on food intake and body weight
Xiao, S., Li, V. L., Lyu, X., Chen, X., Wei, W., Abbasi, F., Knowles, J. W., Tung, A. S.-H., Deng, S., Tiwari, G., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00999-9 · Cited by 92
“…broadly resistant to any and all anorexigenic and anti-obesity stimuli, we treated WT and CNDP2-KO mice with a single dose of recombinant GDF15 protein (4 nmol kg −1 , subcutaneous injection) or a single dose of the GLP-1 receptor agonist semaglutide (10 nmol kg −1 , subcutaneous injection) 33 .”
Asfour, M. H. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00746-z · Cited by 92
Cheang, J. Y., & Moyle, P. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201700781 · Cited by 82
Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin
Callmann, C. E., LeGuyader, C. L. M., Burton, S. T., Thompson, M. P., Hennis, R., Barback, C. V., Henriksen, N. M., Chan, W. C., Jaremko, M. J., Yang, J. Y., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b04272 · Cited by 86
Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes
Zhang, X., Belousoff, M. J., Liang, Y., Danev, R., Sexton, P. M., & Wootten, D. L. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109374 · Cited by 88
Miller, B. S., Blair, J., Rasmussen, M. H., Maniatis, A. K., Kildemoes, R. J., Mori, J., Polak, M., Bang, R. B., Böttcher, V., Stagi, S., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac513 · Cited by 82
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., & Gu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935823 · Cited by 81
“Since DAEs occurred more frequently in semaglutide, it may be due to its longer half-life (165 h), potentially inducing a more abrupt return of hunger when pausing the treatment and leading to permanent discontinuations (Lau et al., 2015; Rubino et al., 2022).”
BackgroundLingvay, I., Desouza, C. V., Lalic, K. S., Rose, L., Hansen, T., Zacho, J., & Pieber, T. R. (2018) · Diabetes Care · doi:10.2337/dc17-2381 · Cited by 81
“Consequently, semaglutide has a half-life of ;1 week (10).”
BackgroundKnerr, L., Prakash, T. P., Lee, R., Drury III, W. J., Nikan, M., Fu, W., Pirie, E., Maria, L. D., Valeur, E., Hayen, A., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c12043 · Cited by 77
Gunnoo, S. B., & Madder, A. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00808a · Cited by 79
Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
Jensen, L., Kupcova, V., Arold, G., Pettersson, J., & Hjerpsted, J. B. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13186 · Cited by 76
“structural modifications prolong the half-life of semaglutide to ~1 week, making it appropriate for once-weekly administration.(7,9) In phase III trials, semaglutide demonstrated superior reductions in”
BackgroundLee, T. S., Park, E. J., Choi, M., Oh, H. S., An, Y., Kim, T. P., Kim, T. H., Shin, B. S., & Shin, S. (2023) · Journal of Chromatography B · doi:10.1016/j.jchromb.2023.123688 · Cited by 80
Li, X., Luo, W., Tang, Y., Wu, J., Zhang, J., Chen, S., Lü, Z., Yu, T., Tang, Y., Wang, F., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103129 · Cited by 83
“Semaglutide is a long-acting GLP-1 analog, approved by the US Food and Drug Administration for treating type 2 diabetes [34].”
BackgroundKalra, S., & Sahay, R. K. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00894-y · Cited by 90
“structural differences that provide extended pharmacokinetics [16] (Fig.”
BackgroundProtein Engineering Strategies for Improved Pharmacokinetics
Rondon, A., Mahri, S., Morales-Yánez, F., Dumoulin, M., & Vanbever, R. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202101633 · Cited by 74
Li, Q., Tuo, X., Li, B., Deng, Z., Qiu, Y., & Xie, H. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117531 · Cited by 72
Wang, D., Yin, F., Li, Z., Zhang, Y., & Chen, S. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03277-2 · Cited by 84
“Semaglutide, a GLP-1 analog, is conjugated to a fatty acid chain, resulting in a significantly longer half-life and enabling once-weekly administration [179].”
Reddy, L. H., Urmann, M., Besenius, M., Ulrich, W., Haack, T., Brun, P., Alié, J., Illel, B., Hortala, L., Vogel, R., et al. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.011 · Cited by 78
Deciphering albumin-directed drug delivery by imaging
Hu, H., Quintana, J. M., Weissleder, R., Parangi, S., & Miller, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114237 · Cited by 73
Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide
Gallwitz, B., & Giorgino, F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645507 · Cited by 70
“Semaglutide has 94% sequence homology with native GLP-1, with three key structural differences that prolong its half-life to approximately one week, without compromising GLP-1 receptor binding (25, 30).”
BackgroundFletcher, M. M., Keov, P., Truong, T. T., Mennen, G., Hick, C. A., Zhao, P., Furness, S. G. B., Kruse, T., Clausen, T. R., Wootten, D., et al. (2021) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000567 · Cited by 68
Self-citationMolecular analysis and therapeutic applications of human serum albumin-fatty acid interactions
Linciano, S., Moro, G., Zorzi, A., & Angelini, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.038 · Cited by 79
Farokhnia, M., Tazare, J., Pince, C. L., Bruns, N., Gray, J. C., Re, V. L., Fiellin, D. A., Kranzler, H. R., Koob, G. F., Justice, A. C., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188314 · Cited by 72
Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery
Yang, P., Zou, H., Chao, E., Sherwood, L., Núñez, V., Keeney, M., Ghartey-Tagoe, E. B., Ding, Z., Quirino, H., Luo, X., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601653113 · Cited by 73
“Nonetheless, the serum half-life of E6 is comparable to that of semaglutide (41), which has a dosing frequency of once a week in humans.”
BackgroundBasalay, M. V., Davidson, S. M., & Yellon, D. M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06915-8 · Cited by 68
Savendahl, L. S., Battelino, T., Brod, M. I., Rasmussen, M. H., Horikawa, R., Juul, R. V., Saenger, P. H., REAL 3 study group, Furthner, D., Piringer, B., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz310 · Cited by 68
Yang, P., Zou, H., Lee, C., Muppidi, A., Chao, E., Fu, Q., Luo, X., Wang, D., Schultz, P. G., & Shen, W. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00768 · Cited by 71
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 65
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 75
Therapeutic advances in obesity management: an overview of the therapeutic interventions
Roomy, M. A., Hussain, K., Behbehani, H. M., Abu-Farha, J., Al-Harris, R., Ambi, A. M., Abdalla, M. A., Al‐Mulla, F., Abu‐Farha, M., & Abubaker, J. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1364503 · Cited by 79
“It is a GLP-1 analogue that has undergone three modi fi cations to extend its half-life, allowing for once-weekly administration (39).”
BackgroundClinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 74
Efficacy and safety of semaglutide for weight management: evidence from the STEP program
Amaro, A., Sugimoto, D., & Wharton, S. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2147326 · Cited by 60
Merkel, R., Hernandez, N. S., Weir, V. R., Zhang, Y., Caffrey, A., Rich, M. T., Crist, R. C., Reiner, B. C., & Schmidt, H. D. (2025) · Science Advances · doi:10.1126/sciadv.adr5051 · Cited by 79
“Nota-bly, exenatide-based GLP-1R agonists have 53% structual homology to endogenous human GLP-1 ( 41 ), while semaglutide, a newer-generation GLP-1R agonist, has 94% structural homology to endogenous human GLP-1 and is less susceptible to degradation by dideptidyl peptidase IV ( 42 ).”
Whole-brain activation signatures of weight-lowering drugs
Hansen, H. H., Perens, J., Roostalu, U., Skytte, J. L., Salinas, C. G., Barkholt, P., Thorbek, D. D., Rigbolt, K. T. G., Vrang, N., Jelsing, J., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101171 · Cited by 66
Characterization and impact of peptide physicochemical properties on oral and subcutaneous delivery
Klepach, A., Tran, H., Mohammed, F. A., & ElSayed, M. E. H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114322 · Cited by 67
Therapeutic peptides: chemical strategies fortify peptides for enhanced disease treatment efficacy
Li, Q., Chao, W., & Qiu, L. (2025) · Amino Acids · doi:10.1007/s00726-025-03454-5 · Cited by 74
“Furthermore, Semaglutide introduces an octadecanoic acid through glutamic acid as a linker on the side chain of the 26th lysine, enhancing its hydrophobicity and significantly extending its half-life to a week (Lau et al. 2015).”
Nilsson, C., Hansen, T. K., Rosenquist, C., Hartmann, B., Kodra, J. T., Lau, J. F., Clausen, T. R., Raun, K., & Sams, A. G. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.01.003 · Cited by 67
Self-citationRecent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G., & Congreve, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00835 · Cited by 60
Controlled release of biologics for the treatment of type 2 diabetes
Gilroy, C. A., Luginbuhl, K. M., & Chilkoti, A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.002 · Cited by 68
“This formulation is acylated at the same Lys26 residue, but with a stearic diacid in place of Liraglutide’s palmitate, which gives it a greater and more stable affinity for albumin[131].”
Molecular engineering of safe and efficacious oral basal insulin
Hubálek, F., Refsgaard, H. H. F., Gram-Nielsen, S., Madsen, P., Nishimura, E., Münzel, M., Brand, C. L., Stidsen, C. E., Claussen, C. H., Wulff, E. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17487-9 · Cited by 69
Self-citationHausner, H., Derving Karsbøl, J., Holst, A. G., Jacobsen, J. B., Wagner, F.-D., Golor, G., & Anderson, T. W. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0532-6 · Cited by 62
“Structurally, it has 94% homology to native GLP-1, but with important structural modifications that make semaglutide suitable for once-weekly subcutaneous administration, with fully retained potency [10].”
BackgroundObesity medications in development
Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62
“covalent association to provide a half-life of 165 h [30].”
BackgroundRecent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Tan, H., Su, W., Zhang, W., Wang, P., Sattler, M., & Zou, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190206105232 · Cited by 64
Yang, W., Gadgil, P., Krishnamurthy, V. R., Landis, M. S., Mallick, P., Patel, D., Patel, P. J., Reid, D. L., & Sánchez-Félix, M. (2020) · The AAPS Journal · doi:10.1208/s12248-019-0402-2 · Cited by 67
Hormonal Gut–Brain Signaling for the Treatment of Obesity
Roh, E., & Choi, K. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043384 · Cited by 66
“Semaglutide has 94% sequence homology with native GLP-1 and a longer half-life, allowing weekly administration [130].”
BackgroundPennington, M. W., Zell, B., & Bai, C. J. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100071 · Cited by 61
Human serum albumin binders: A piggyback ride for long-acting therapeutics
Ullah, A., Shin, G., & Lim, S. I. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103738 · Cited by 69
Molecular Modelling in Bioactive Peptide Discovery and Characterisation
Agoni, C., Fernández-Díaz, R., Timmons, P. B., Adelfio, A., Gómez, H., & Shields, D. C. (2025) · Biomolecules · doi:10.3390/biom15040524 · Cited by 69
“For example, the more stable GLP-1 peptide analogue semaglutide exhibits a lower degradation rate by DPP4 protease and increased binding affinity to albumin [133].”
DeSouza, C., Cariou, B., Garg, S., Lausvig, N., Navarria, A., & Fonseca, V. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz072 · Cited by 57
Oral Drug Delivery: Conventional to Long Acting New-Age Designs
Bhutani, U., Basu, T., & Majumdar, S. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.02.008 · Cited by 64
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 96
“Both dulaglutide and semaglutide have bigger molecules, which results in a longer half-life [91].”
BackgroundDiscovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog
Guo, W., Xu, Z., Zou, H., Li, F., Li, Y., Feng, J., Zhu, Z., Zheng, Q., Zhu, R., Wang, B., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101762 · Cited by 58
“Analog Sequence modification Fatty acid Semaglutide Aib8 C18 diacid M0 Val8 C18 diacid M1 Val8 C18 diacid M2 Val8 C18 diacid M3 Val8 C18 diacid M4 (ecnoglutide) Val8 C18 diacid M5 Val8 C18 diacid M6 Val8 C18 diacid M7 Val8 C18 diacid a Potency of inducing GLP-1 receptor-mediated cAMP production in RIN-m5F (rat islet c…”
BackgroundYang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
“It becomes protease-resistant by changing the amino acid at position 8 and an extended spacer for the attached fatty acid which prolongs the half-time in the blood (164), and is a once-weekly GLP-1R agonist for T2DM.”
BackgroundSemaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet
Duan, X., Zhang, L., Liao, Y., Lin, Z., Guo, C., Luo, S., Wang, F., Zou, Z., Zeng, Z., Chen, C., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176440 · Cited by 66
Lucey, M., Pickford, P., Bitsi, S., Minnion, J., Ungewiss, J., Schoeneberg, K., Rutter, G. A., Bloom, S. R., Tomas, A., & Jones, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.100991 · Cited by 55
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Self-citationThe discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity
Friedman, J. M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2415550121 · Cited by 68
From lead to market: chemical approaches to transform peptides into therapeutics
Gare, C. L., White, A. M., & Malins, L. R. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.01.009 · Cited by 67
Musaimi, O. A., Shaer, D. A., de la Torre, B. G., & Alberício, F. (2018) · Pharmaceuticals · doi:10.3390/ph11020042 · Cited by 67
“Liraglutide is the first once‐daily glucagon‐like peptide‐1 analogue designed to resist enzymatic degradation and thus have a longer half‐life [26,27,30].”
BackgroundHe, Z., Nie, T., Hu, Y., Zhou, Y., Zhu, J., Liu, Z., Liu, L., Leong, K. W., Chen, Y., & Mao, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.014 · Cited by 57
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01106-4 · Cited by 55
Wang, L. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s358989 · Cited by 56
“the second residue of exenatide is Gly rather than Ala; thus, it can circumvent the degradation of dipeptidyl peptidase-4 (DPP-4) and has a prolonged intravenous half-life of 30 min and a 2–3 h half-life after subcutaneous administration.(2) Liraglutide is designed to bind to human albumin via a C16 fatty acid and a s…”
InfluentialBækdal, T. A., Breitschaft, A., Donsmark, M., Maarbjerg, S. J., Søndergaard, F. L., & Borregaard, J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01078-y · Cited by 48
Savendahl, L. S., Battelino, T., Rasmussen, M. H., Brod, M. I., Saenger, P. H., & Horikawa, R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab928 · Cited by 57
Iwai, S., Kaji, K., Nishimura, N., Kubo, T., Tomooka, F., Shibamoto, A., Suzuki, J., Tsuji, Y., Fujinaga, Y., Kitagawa, K., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166770 · Cited by 49
Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
Frémaux, J., Venin, C., Mauran, L., Zimmer, R., Guichard, G., & Goudreau, S. R. (2019) · Nature Communications · doi:10.1038/s41467-019-08793-y · Cited by 60
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Yang, B., Gelfanov, V. M., El, K., Chen, A., Rohlfs, R., DuBois, B., Kruse Hansen, A. M., Perez-Tilve, D., Knerr, P. J., D'Alessio, D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101638 · Cited by 55
“Inspired by long-acting GLP-1R agonists such as semaglutide [29], we began by replacing the C16 acylation with an octadecanoyl protractor bearing a terminal carboxylate (C18-OH) and explored different compositions of the linker between the peptide backbone and the protractor, with the ambition that the C18-OH protract…”
MethodStructural principles of insulin formulation and analog design: A century of innovation
Jarosinski, M. A., Dhayalan, B., Chen, Y., Chatterjee, D., Varas, N., & Weiss, M. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101325 · Cited by 58
Kuril, A. K., Vashi, A., & Subbappa, P. K. (2024) · Journal of Peptide Science · doi:10.1002/psc.3648 · Cited by 55
Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54
The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
Rasmussen, M. F. (2020) · Diabetology International · doi:10.1007/s13340-019-00423-8 · Cited by 57
“These differences prolong the half-life of semaglutide to approximately 1 week, without compromising GLP-1 receptor binding [25].”
BackgroundSolis‐Herrera, C., Kane, M. P., & Triplitt, C. L. (2023) · Clinical Diabetes · doi:10.2337/cd22-0118 · Cited by 61
“…once-daily lira-glutide with 97% homology to native GLP-1 to the development of analogs for once-weekly administration achieved through the use of an Fc fusion protein (dula-glutide) or advances in fatty acid acylation – based protraction technology (semaglutide) to extend the half-life (15,33,34).”
BackgroundNestor, J. J., Parkes, D., Feigh, M., Suschak, J. J., & Harris, M. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-10577-2 · Cited by 53
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes
Petri, K. C. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13358 · Cited by 53
“has three structural modifications that prolong its half-life to ~1 week, making it appropriate for once-weekly administration.(4,5) In the sema-”
BackgroundBrain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 56
“Building on the success of exenatide and liraglutide, additional GLP-1 receptor agonists have since been developed, including dulaglutide [38], lixisenatide, SMG [39], and tirzepatide [40].”
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
Hoogenboezem, E. N., Patel, S. S., Lo, J. H., Cavnar, A. B., Babb, L. M., Francini, N., Gbur, E. F., Patil, P., Colazo, J. M., Michell, D. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45609-0 · Cited by 52
“These fi ndings are consistent with previous reports showing the in fl uence of linker architecture on the albumin af fi nity of semaglutide, a therapeutic GLP-1 agonist 41 , and highlight the impact of the EG repeats within the linker region.”
Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
Overgaard, R. V., Delff, P. H., Petri, K. C. C., Anderson, T. W., Flint, A., & Ingwersen, S. H. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0581-y · Cited by 47
Musaimi, O. A. (2024) · Biomolecules · doi:10.3390/biom14030264 · Cited by 53
Evers, A., Bossart, M., Pfeiffer-Marek, S., Elvert, R., Schreuder, H., Kurz, M., Stengelin, S., Lorenz, M., Herling, A., Konkar, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00292 · Cited by 50
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 48
Review: Glucose-sensitive insulin
Høeg-Jensen, T. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101107 · Cited by 58
“The myristoyl conjugate insulin detemir [118,119] was the first albumin-binding peptide conjugate to reach the market, followed by liraglutide (GLP-1) [120], insulin degludec [13], and semaglutide (GLP1) [7].”
BackgroundShi, F.-H., Li, H., Cui, M., Zhang, Z.-L., Gu, Z.-C., & Liu, X.-Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00576 · Cited by 50
“Otherwise, hypoglycemia is a serious challenge and obstacle in the T2DM treatment.”
BackgroundInfluentialNovel formulations and drug delivery systems to administer biological solids
Zhang, Y., Davis, D. A., AboulFotouh, K., Wang, J., Williams, D., Bhambhani, A., Zakrewsky, M., Maniruzzaman, M., Cui, Z., & Williams, R. O. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.011 · Cited by 52
Yale, J.-F., Bodholdt, U., Catarig, A.-M., Catrina, S., Clark, A., Ekberg, N. R., Erhan, U., Holmes, P., Knudsen, S. T., Liutkus, J., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002619 · Cited by 50
Self-citationKnerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Østergaard, S., Paulsson, J. F., Kofoed, J., Zosel, F., Olsen, J., Jeppesen, C. B., Spetzler, J. C., Ynddal, L., Schleiss, L. G., Christoffersen, B. Ø., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00654-3 · Cited by 54
Self-citation
Metadata
- Authors
- Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark
- Corresponding author
- Lau, Jesper
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-09-11
- Volume
- 58
- Issue
- 18
- Pages
- 7370-7380
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2162140339
- Cited by
- 1,105
- References
- 36
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 151 · 2023: 97 · 2022: 106 · 2021: 84 · 2020: 88 · 2019: 71 · 2018: 77 · 2017: 46 · 2016: 30 · 2015: 2
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, liraglutide, glucagon-like peptide-1 analogues, GLP-1 receptor, albumin binding, weekly dosing, plasma half-life, metabolic stability, fatty acid acylation, type 2 diabetes, obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Cell Line, Glucagon-Like Peptides, Half-Life, Cricetinae, Humans, Injections, Subcutaneous, Male, Mice, Obese, Models, Molecular, Structure-Activity Relationship, Swine, Swine, Miniature, Rats, Sprague-Dawley, Crystallography, X-Ray, Glucagon-Like Peptide 1, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.